FP
EGRX

Foundry Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Foundry Partners’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-84,325
Closed -$3.75M – 332
2022
Q2 		$3.75M Hold
84,325
– – 0.23% 121
2022
Q1 		$4.17M Buy
84,325
+22,660
+37% +$1.09M 0.21% 133
2021
Q4 		$3.14M Sell
61,665
-2,020
-3% -$105K 0.11% 205
2021
Q3 		$3.55M Sell
63,685
-2,900
-4% -$143K 0.13% 201
2021
Q2 		$2.85M Sell
66,585
-12,186
-15% -$503K 0.1% 232
2021
Q1 		$3.29M Sell
78,771
-2,905
-4% -$135K 0.11% 226
2020
Q4 		$3.8M Buy
81,676
+4,445
+6% +$208K 0.15% 194
2020
Q3 		$3.28M Buy
77,231
+2,158
+3% +$94.4K 0.16% 182
2020
Q2 		$3.6M Sell
75,073
-9,504
-11% -$474K 0.18% 168
2020
Q1 		$3.89M Buy
84,577
+14,220
+20% +$714K 0.22% 141
2019
Q4 		$4.23M Sell
70,357
-5,803
-8% -$346K 0.16% 189
2019
Q3 		$4.31M Buy
76,160
+2,775
+4% +$156K 0.18% 185
2019
Q2 		$4.09M Buy
73,385
+65,785
+866% +$3.43M 0.16% 192
2019
Q1 		$384K Hold
7,600
– – 0.02% 358
2018
Q4 		$306K Buy
7,600
+2,350
+45% +$121K 0.01% 368
2018
Q3 		$364K Sell
5,250
-415
-7% -$31.5K 0.01% 363
2018
Q2 		$429K Hold
5,665
– – 0.02% 352
2018
Q1 		$298K Sell
5,665
-1,650
-23% -$95.9K 0.01% 375
2017
Q4 		$391K Buy
7,315
+3,565
+95% +$198K 0.02% 349
2017
Q3 		$224K Buy
+3,750
New +$227K 0.01% 383

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Foundry Partners's EGRX Position: Q3 2022 in Review

Foundry Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2022, closing a stake of 84,325 shares — an estimated $3.75M sold.

Foundry Partners first reported a position in EGRX in Q3 2017 and held it in 20 quarters. The position peaked at $4.31M in Q3 2019. 153 funds tracked by Wall St. Rank hold EGRX as of Q3 2022.

  • Foundry Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • Foundry Partners sold 84,325 Eagle Pharmaceuticals, Inc. shares in Q3 2022, an estimated $3.75M.
  • Foundry Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2017 and held it in 20 quarters.
  • Foundry Partners's Eagle Pharmaceuticals, Inc. position peaked at $4.31M in Q3 2019.
  • 153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2022.

Based on Foundry Partners's 13F filing for Q3 2022, filed 21 Oct 2022.